Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Receivables (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Receivables for 3 consecutive years, with $200000.0 as the latest value for Q4 2025.

  • Quarterly Receivables fell 49.62% to $200000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $200000.0 through Dec 2025, down 49.62% year-over-year, with the annual reading at $200000.0 for FY2025, 49.62% down from the prior year.
  • Receivables for Q4 2025 was $200000.0 at Inhibrx Biosciences, down from $727000.0 in the prior quarter.
  • The five-year high for Receivables was $1.4 million in Q4 2023, with the low at $200000.0 in Q4 2025.
  • Average Receivables over 3 years is $780571.4, with a median of $727000.0 recorded in 2025.
  • The sharpest move saw Receivables plummeted 71.34% in 2024, then increased 8.18% in 2025.
  • Over 3 years, Receivables stood at $1.4 million in 2023, then tumbled by 71.34% to $397000.0 in 2024, then crashed by 49.62% to $200000.0 in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $200000.0, $727000.0, and $967000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.